Hookipa Biotech AG, a Vienna, Austria-based developer of a new class of vaccines, raised €20m ($27.5m) in Series B equity financing.
The roud was led by existing investors Sofinnova Partners and Forbion Capital Partners with participation from three new investors Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners. In conjunction with the funding, Dr. Frank Kalkbrenner from the Boehringer Ingelheim Venture Fund, joined as a new member of the company’s Supervisory Board. Dr. Yuji Iizawa from Takeda Ventures and Dr. Markus Hosang from BioMedPartners joined as observers.
Led by Dr. Katherine Cohen, Chief Executive Officer, Hookipa Biotech has developed Vaxwave®, a novel and proprietary viral vector platform with capacity for the stimulation of antibody and CD8+ T cell immunity. The company’s lead product candidate based on this platform, HB101, is a vaccine against cytomegalovirus (CMV) that is currently in advanced pre-clinical development and testing.
Hoopika intends to use the funds to progress HB101 into Phase I clinical testing and to further industrialize Vaxwave.